Efforts Towards Patent Protection to Drive ADC Market
In US alone, patents of biologics worth US$ 67 Billion will expire before 2020. These biologics majorly include the blockbuster drugs of the pharma giants. As these drugs approach their patent expiry, pharma giants are looking for ways to protect their heavily invested upon innovations. One such strategy is patent fencing or patent blocking. Following the same strategy, Roche, has already released Kadcyla, an ADC, based on its blockbuster drug Herceptin for breast cancer. Big pharma players are therefore, using...
View full press release